Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Patent awarded for therapeutic uses of interleukin-9 receptor protein
September 1st, 2003
Genaera Corp. (GENR) announced issuance by the United States Patent and Trademark Office of patent number 6,602,850 covering the use of certain soluble human interleukin-9 (IL-9) receptor protein variants as a method for treating bronchial hyperresponsiveness and asthma. Bronchial hyperresponsiveness is the excess reaction of airway narrowing associated with the symptoms of a variety of respiratory illnesses, including asthma. "This patent is another component of our intellectual property strategy to protect the use of the various therapeutic alternatives that could neutralize IL-9," noted Roy C. Levitt, president and CEO. "It is important to have...
Source: Health & Medicine Week (2003-09-01)
|
